Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03823742 · ClinicalTrials.gov registry record · NA
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
A NA study of Irritable Bowel Syndrome and Functional Gastrointestinal Disorders, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 2
- Study locations
NCT03823742: Recruiting NA study of Irritable Bowel Syndrome and Functional Gastrointestinal Disorders, sponsored by Baylor College of Medicine.
NCT03823742 is a NA study of Irritable Bowel Syndrome and Functional Gastrointestinal Disorders that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 250 participants, above the 139-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (80% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03823742, a NA study of Irritable Bowel Syndrome and Functional Gastrointestinal Disorders, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is find out if we can use simple tests (biomarkers) to tell us if a specific child would benefit most from CBT or from the low FODMAPs diet.
Primary Outcome
Abdominal pain frequency or severity
Conditions Studied
Interventions
- OTHER Cognitive Behavioral Therapy
- OTHER Low FODMAP Diet
Study Locations (2)
Texas
- Children's Nutrition Research Center - Houston
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2019-02-22 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT03823742 shows while recruiting
NCT03823742 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 139-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (80% higher).
The record links to 6 conditions, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Cognitive Behavioral Therapy is the first listed.
NCT03823742 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03823742 about?
NCT03823742 is a clinical study titled "Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?". The purpose of this study is find out if we can use simple tests (biomarkers) to tell us if a specific child would benefit most from CBT or from the low FODMAPs diet.
What is the current status of trial NCT03823742?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2019-02-22. Estimated completion is 2025-12-31.
What conditions does trial NCT03823742 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome, Functional Gastrointestinal Disorders, Functional Abdominal Pain Syndrome, Functional Bowel Disorder, Functional Abdominal Pain Disorders.
What interventions are being tested in trial NCT03823742?
The interventions under investigation include: Cognitive Behavioral Therapy (OTHER), Low FODMAP Diet (OTHER).
Who is sponsoring clinical trial NCT03823742?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03823742 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03823742's enrollment target sits among peer trials
250 9th of 47 higher than 38 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GI Alpha-Gal Study
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
-
IBS Skin Patch Test Food Allergy Study
RECRUITING · NA
-
Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome
RECRUITING · NA
-
Well-being in IBS: Strengths and Happiness (WISH) 2.0
RECRUITING · NA
-
Mechanisms of Gulf War Illness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI